

## Consolidated Profit & Loss Account For Continuing Operations

For the year ended 31 December	2002 \$m	2001 (Restated) \$m
<b>Sales</b>	17,841	16,222
Cost of sales	(4,520)	(4,198)
Distribution costs	(141)	(122)
Research and development	(3,069)	(2,687)
Selling, general and administrative expenses	(5,998)	(5,427)
Other operating income	243	368
<b>Operating profit before exceptional items</b>	4,356	4,156
Exceptional items charged to operating profit	(350)	(202)
Operating profit	4,006	3,954
Share of joint ventures' and associates' operating profits	-	-
Profit on sale of fixed assets	-	10
Net interest and dividend income	31	113
Profit on ordinary activities before taxation	4,037	4,077
<b>Profit before taxation before exceptional items</b>	4,387	4,269
Exceptional items charged to profit before taxation	(350)	(192)
Taxation	(1,177)	(1,160)
<b>Profit on ordinary activities after taxation</b>	2,860	2,917
Attributable to minorities	(24)	(11)
<b>Net profit for the year</b>	2,836	2,906
Dividends to Shareholders	(1,206)	(1,225)
Earnings per Ordinary Share before exceptional items	\$1.84	\$1.73
Earnings per Ordinary Share	\$1.64	\$1.65
Diluted earnings per Ordinary Share	\$1.64	\$1.65
Weighted average number of Ordinary Shares in issue (millions)	1,733	1,758
Diluted average number of Ordinary Shares in issue (millions)	1,735	1,761

## Consolidated Profit & Loss Account For Continuing Operations

For the <b>quarter</b> ended 31 December	2002 \$m	2001 (Restated) \$m
<b>Sales</b>	4,901	4,366
Cost of sales	(1,253)	(1,132)
Distribution costs	(39)	(33)
Research and development	(892)	(732)
Selling, general and administrative expenses	(1,661)	(1,443)
Other operating income	18	64
<b>Operating profit before exceptional items</b>	1,074	1,090
Exceptional items charged to operating profit	(350)	(76)
Operating profit	724	1,014
Share of joint ventures' and associates' operating profits	-	-
Profit on sale of fixed assets	-	-
Net interest and dividend income	7	12
Profit on ordinary activities before taxation	731	1,026
<b>Profit before taxation before exceptional items</b>	1,081	1,102
Exceptional items charged to profit before taxation	(350)	(76)
Taxation	(291)	(296)
<b>Profit on ordinary activities after taxation</b>	440	730
Attributable to minorities	(12)	(4)
<b>Net profit for the period</b>	428	726
Dividends to Shareholders	(808)	(820)
Earnings per Ordinary Share before exceptional items	\$0.45	\$0.45
Earnings per Ordinary Share	\$0.25	\$0.42
Diluted earnings per Ordinary Share	\$0.25	\$0.42
Weighted average number of Ordinary Shares in issue (millions)	1,723	1,750
Diluted average number of Ordinary Shares in issue (millions)	1,725	1,752

## Consolidated Balance Sheet

At 31 December	2002 \$m	2001 (Restated) \$m
<b>Fixed assets</b>		
Tangible fixed assets	6,597	5,409
Goodwill and intangible assets	2,807	2,700
Fixed asset investments	46	23
	<u>9,450</u>	<u>8,132</u>
<b>Current assets</b>		
Stocks	2,593	2,402
Debtors	4,845	4,139
Cash and short-term investments	4,688	3,823
	<u>12,126</u>	<u>10,364</u>
<b>Total assets</b>	<u>21,576</u>	<u>18,496</u>
<b>Creditors due within one year</b>		
Short-term borrowings and current instalments of loans	(516)	(321)
Other creditors	(7,699)	(6,159)
	<u>(8,215)</u>	<u>(6,480)</u>
<b>Net current assets</b>	<u>3,911</u>	<u>3,884</u>
<b>Total assets less current liabilities</b>	<u>13,361</u>	<u>12,016</u>
<b>Creditors due after more than one year</b>		
Loans	(328)	(635)
Other creditors	(34)	(152)
<b>Provisions for liabilities and charges</b>	(1,773)	(1,600)
	<u>(2,135)</u>	<u>(2,387)</u>
<b>Net assets</b>	<u>11,226</u>	<u>9,629</u>
<b>Capital and reserves</b>		
Shareholders' funds – equity interests	11,172	9,586
Minority equity interests	54	43
<b>Shareholders' funds and minority interests</b>	<u>11,226</u>	<u>9,629</u>

## Statement of Total Recognised Gains and Losses

For the year ended 31 December	2002 \$m	2001 (Restated) \$m
Net profit for the financial year	2,836	2,906
Exchange adjustments on net assets	1,106	(502)
Translation differences on foreign currency borrowings	6	18
Tax on translation differences on foreign currency borrowings	(2)	(6)
<b>Total recognised gains and losses for the financial year</b>	<b>3,946</b>	<b>2,416</b>
Prior Year adjustment (FRS 19 Deferred Tax)	(200)	
Total gains and losses recognised since last Annual Report	3,746	

## Consolidated Cash Flow Statement

For the year ended 31 December	2002 \$m	2001 \$m
<b>Cash flow from operating activities</b>		
Operating profit before exceptional items	4,356	4,156
Depreciation and amortisation	960	860
Decrease/(increase) in working capital	305	(1,006)
Other non-cash movements	65	120
<b>Net cash inflow from operating activities before exceptional items</b>	<b>5,686</b>	<b>4,130</b>
Outflow related to exceptional items	(93)	(368)
<b>Net cash inflow from operating activities</b>	<b>5,593</b>	<b>3,762</b>
Returns on investments and servicing of finance	35	156
Tax paid	(795)	(792)
Capital expenditure and financial investment	(1,543)	(1,543)
Acquisitions and disposals	-	(44)
Equity dividends paid to Shareholders	(1,234)	(1,236)
<b>Net cash inflow before management of liquid resources and financing</b>	<b>2,056</b>	<b>303</b>
<b>Management of liquid resources</b>		
Movement in short-term investments and fixed deposits (net)	(806)	260
<b>Financing</b>	<b>(1,272)</b>	<b>(959)</b>
<b>Decrease in cash in the year</b>	<b>(22)</b>	<b>(396)</b>

## Reconciliation of Cash Flow to Net Cash Funds

For the year ended 31 December	2002 \$m	2001 \$m
Net funds at 1 January	2,867	3,605
Net cash flows before management of liquid resources and financing	2,056	303
Net cash flows from share issues and repurchases	(1,154)	(994)
Exchange	75	(47)

---

**Net funds at 31 December**

---

3,844

2,867

---

## Notes to the Preliminary Announcement

### 1 BASIS OF PREPARATION AND ACCOUNTING POLICIES

The results for the full year ended 31 December 2002 have been prepared in accordance with UK generally accepted accounting principles. The accounting policies applied are those set out in AstraZeneca PLC's 2001 Annual Report and Form 20-F except that, in the current period, AstraZeneca adopted Financial Reporting Standard No. 19 "Deferred Tax". Prior periods have been restated and the effects of this restatement were to reduce profits for the full year ended 31 December 2001 by \$61m and reduce net assets at that date by \$193m. The table below illustrates the effect on EPS before exceptional items of this restatement.

The results for the year ended 31 December 2002 presented in this preliminary announcement are extracted from, and are consistent with, those in the Group's audited financial statements for the year ended 31 December 2002 and those financial statements will be delivered to the Registrar of Companies following the Company's Annual General Meeting.

#### 2001 TAXATION AND EARNINGS PER SHARE BEFORE EXCEPTIONAL ITEMS

	Q1 2001	Q2 2001	Q3 2001	Q4 2001	Year
Tax charge before adoption of FRS 19 (\$m)	(316)	(269)	(286)	(282)	(1,153)
Tax charge after adoption of FRS 19 (\$m)	(315)	(289)	(295)	(315)	(1,214)
Published EPS before adoption of FRS 19 (\$)	0.45	0.42	0.43	0.47	1.77
Adjusted EPS after adoption of FRS 19 (\$)	0.45	0.41	0.42	0.45	1.73

As part of AstraZeneca's objective to align with accounting best practice, cash discounts arising from prompt payment of invoices have been reclassified from cost of sales to sales. Comparatives have also been reclassified for consistency of presentation. Both sales and cost of sales have been reduced by \$74m in the fourth quarter 2002 and \$287m in the current year (2001 \$258m, 2000 \$221m). Furthermore, neither profits nor net assets have been affected. The change has minimal impact on previously stated sales growth rates. The reclassified quarterly sales figures are presented below. Additional detail at the product and territorial level are available on the AstraZeneca website.

#### 2002 SALES AND COST OF SALES RECLASSIFIED FOR CASH DISCOUNTS

	Q1 2002	Q2 2002	Q3 2002
Sales as previously reported (\$m)	4,421	4,382	4,350
Reclassified Sales (\$m)	4,346	4,312	4,282
Cost of Sales as previously reported (\$m)	1,169	1,130	1,181
Reclassified Cost of Sales (\$m)	1,094	1,060	1,113
Operating margin as reported	29.3%	24.3%	21.2%
Adjusted operating margin	29.8%	24.7%	21.5%

#### 2001 SALES AND COST OF SALES RECLASSIFIED FOR CASH DISCOUNTS

	Q1 2001	Q2 2001	Q3 2001	Q4 2001	Year
Sales as previously reported (\$m)	3,991	4,099	3,950	4,440	16,480
Reclassified Sales (\$m)	3,933	4,035	3,888	4,366	16,222
Cost of Sales as previously reported (\$m)	1,074	1,112	1,064	1,206	4,456
Reclassified Cost of Sales (\$m)	1,016	1,048	1,002	1,132	4,198
Operating margin as previously reported	26.4%	24.3%	25.7%	24.5%	25.2%
Adjusted operating margin	26.8%	24.7%	26.1%	25.0%	25.6%

Information in this preliminary announcement does not constitute statutory accounts of the Group within the meaning of Section 240 of the Companies Act 1985. Statutory accounts for the year ended 31 December 2001 have been filed

with the Registrar of Companies. The auditor's report on those accounts was unqualified and did not contain any statement under Section 237 of the Companies Act 1985.

## 2 JOINT VENTURES AND ASSOCIATES

The Group's share of joint ventures' sales for the year ended 31 December 2002 amounted to \$191m and \$183m for the comparative period. Share of joint ventures' operating profits for the year ended 31 December 2001 and 2002 amounted to nil.

## 3 ANALYSIS OF EXCEPTIONAL ITEMS CHARGED TO OPERATING PROFIT

	2002 \$m	2001 \$m
Accrual related to Zoladex investigations	350	-
Synergy and integration charge	-	202
	350	202

## 4 RECONCILIATION OF MOVEMENTS IN SHAREHOLDERS' FUNDS

For the year ended 31 December	2002 \$m	2001 (Restated) \$m
Shareholders' funds at beginning of year (originally \$9,786m before deducting prior period adjustment of \$200m)	9,586	9,382
Net profit for the year	2,836	2,906
Dividends to Shareholders	(1,206)	(1,225)
	1,630	1,681
Issue of AstraZeneca PLC Ordinary Shares	36	86
Repurchase of AstraZeneca PLC Ordinary Shares	(1,190)	(1,080)
Foreign currency adjustment	1,110	(483)
Net addition to Shareholders' funds	1,586	204
Shareholders' funds at end of year	11,172	9,586

## 5 NET CASH FUNDS

The table below provides an analysis of net cash funds and a reconciliation of net cash flow to movement in net cash funds.

	At 31 Dec 2001 \$m	Cash flow \$m	Other non-cash \$m	Exchange movement s \$m	At 31 Dec 2002 \$m
Loans due after 1 year	(635)	28	279	-	(328)
Current instalments of loans	(107)	77	(279)	(5)	(314)
Total loans	(742)	105	-	(5)	(642)
Short-term investments	3,118	806	-	38	3,962
Cash	705	(18)	-	39	726
Overdrafts	(195)	(4)	-	(3)	(202)
Short-term borrowings, excluding overdrafts	(19)	13	-	6	-
	3,609	797	-	80	4,486
<b>Net cash funds</b>	2,867	902	-	75	3,844
Issue of AstraZeneca PLC Ordinary Shares		(36)			
Repurchase of AstraZeneca PLC Ordinary Shares		(1,190)			

Shares	1,190
<b>Net cash inflow before management of liquid resources and financing</b>	<b>2,056</b>

## 6 FULL YEAR TERRITORIAL SALES ANALYSIS

	Full Year 2002 \$m	Full Year 2001 \$m	% Growth	
			Actual	Constant Currency
USA	9,351	8,483	10	10
Canada	570	525	9	10
North America	9,921	9,008	10	10
France	1,140	967	18	13
UK	623	759	(18)	(20)
Germany	699	682	2	(2)
Italy	765	638	20	16
Sweden	285	263	8	3
Europe others	2,183	1,929	13	8
Total Europe	5,695	5,238	9	5
Japan	977	851	15	21
Rest of World	1,248	1,125	11	15
Total	17,841	16,222	10	9

## 7 FOURTH QUARTER TERRITORIAL SALES ANALYSIS

	4 <sup>th</sup> Quarter 2002 \$m	4 <sup>th</sup> Quarter 2001 \$m	% Growth	
			Actual	Constant Currency
USA	2,564	2,219	16	16
Canada	147	142	4	5
North America	2,711	2,361	15	15
France	320	266	20	12
UK	147	219	(33)	(37)
Germany	196	179	9	2
Italy	214	181	18	10
Sweden	75	64	17	-
Europe others	576	530	9	2
Total Europe	1,528	1,439	6	(1)
Japan	314	260	21	27
Rest of World	348	306	14	19
Total	4,901	4,366	12	10

## 8 FULL YEAR PRODUCT SALES ANALYSIS

	World				US	
	Full Year 2002 \$m	Full Year 2001 \$m	Actual Growth %	Constant Currency Growth %	Full Year 2002 \$m	Actual Growth %
<b>Gastrointestinal:</b>						
Losec	4,623	5,578	(17)	(18)	2,847	(21)
Nexium	1,978	568	n/m	n/m	1,525	n/m
Others	63	44	43	38	20	n/m
<b>Total Gastrointestinal</b>	<b>6,664</b>	<b>6,190</b>	<b>8</b>	<b>7</b>	<b>4,392</b>	<b>8</b>
<b>Cardiovascular:</b>						
Zestril	877	1,067	(18)	(18)	467	(24)
Seloken	901	711	27	27	617	43
Atacand	569	410	39	36	206	37
Plendil	489	463	6	5	209	6
Tenormin	370	404	(8)	(7)	52	(2)
Others	363	428	(15)	(18)	13	(82)
<b>Total Cardiovascular</b>	<b>3,569</b>	<b>3,483</b>	<b>2</b>	<b>1</b>	<b>1,564</b>	<b>3</b>
<b>Respiratory:</b>						
Pulmicort	812	766	6	5	361	35
Rhinocort	299	265	13	13	211	19
Symbicort	299	83	n/m	n/m	-	-
Accolate	144	143	1	2	104	5
Oxis	120	127	(6)	(9)	-	-
Others	144	155	(7)	(9)	-	-
<b>Total Respiratory</b>	<b>1,818</b>	<b>1,539</b>	<b>18</b>	<b>16</b>	<b>676</b>	<b>24</b>
<b>Oncology:</b>						
Zoladex	794	718	11	12	212	7
Casodex	644	561	15	15	180	(23)
Nolvadex	480	618	(22)	(21)	337	(27)
Arimidex	331	188	76	75	134	127
Iressa	67	-	n/m	n/m	-	-
Faslodex	35	-	n/m	n/m	35	n/m
Others	18	26	(31)	(31)	-	-
<b>Total Oncology</b>	<b>2,369</b>	<b>2,111</b>	<b>12</b>	<b>12</b>	<b>898</b>	<b>(6)</b>
<b>CNS:</b>						
Seroquel	1,145	685	67	67	927	67
Zomig	328	273	20	19	177	20
Others	32	22	45	40	7	17
<b>Total CNS</b>	<b>1,505</b>	<b>980</b>	<b>54</b>	<b>53</b>	<b>1,111</b>	<b>57</b>
<b>Pain, Infection and Other Pharma:</b>						
Diprivan	443	456	(3)	(3)	216	3
Merrem	285	227	26	26	59	9
Local anaesthetics	432	434	-	-	113	(12)
Other Pharma Products	258	379	(32)	(31)	75	(32)
<b>Total Pain, Infection and Other Pharma</b>	<b>1,418</b>	<b>1,496</b>	<b>(5)</b>	<b>(5)</b>	<b>463</b>	<b>(8)</b>
Salick Health Care	233	194	20	20	233	20

Astra Tech	151	126	20	14	11	38
Marlow Foods	114	103	11	8	3	-
<b>Total</b>	<b>17,841</b>	<b>16,222</b>	<b>10</b>	<b>9</b>	<b>9,351</b>	<b>10</b>

n/m not meaningful

## 9 FOURTH QUARTER PRODUCT SALES ANALYSIS

	World				US	
	4 <sup>th</sup> Quarter 2002 \$m	4 <sup>th</sup> Quarter 2001 \$m	Actual Growth %	Constant Currency Growth %	4 <sup>th</sup> Quarter 2002 \$m	Actual Growth %
<b>Gastrointestinal:</b>						
Losec	1,115	1,372	(19)	(20)	684	(17)
Nexium	686	278	n/m	n/m	521	n/m
Others	18	14	29	15	7	n/m
<b>Total Gastrointestinal</b>	<b>1,819</b>	<b>1,664</b>	<b>9</b>	<b>7</b>	<b>1,212</b>	<b>14</b>
<b>Cardiovascular:</b>						
Zestril	144	256	(44)	(44)	46	(68)
Seloken	263	165	59	60	182	107
Atacand	160	124	29	24	55	15
Plendil	139	136	2	-	63	(6)
Tenormin	95	104	(9)	(8)	10	-
Others	93	115	(19)	(29)	(1)	n/m
<b>Total Cardiovascular</b>	<b>894</b>	<b>900</b>	<b>(1)</b>	<b>(3)</b>	<b>355</b>	<b>(7)</b>
<b>Respiratory:</b>						
Pulmicort	237	203	17	14	120	62
Rhinocort	76	74	3	3	54	2
Symbicort	105	49	n/m	n/m	-	-
Accolate	52	30	73	73	41	128
Oxis	29	33	(12)	(18)	-	-
Others	38	40	(5)	(10)	-	-
<b>Total Respiratory</b>	<b>537</b>	<b>429</b>	<b>25</b>	<b>21</b>	<b>215</b>	<b>48</b>
<b>Oncology:</b>						
Zoladex	206	205	-	-	55	8
Casodex	184	173	6	5	46	(35)
Nolvadex	138	181	(24)	(24)	99	(27)
Arimidex	92	51	78	75	32	167
Iressa	41	-	n/m	n/m	-	-
Faslodex	16	-	n/m	n/m	16	n/m
Others	4	4	-	-	-	n/m
<b>Total Oncology</b>	<b>681</b>	<b>614</b>	<b>11</b>	<b>11</b>	<b>248</b>	<b>(8)</b>
<b>CNS:</b>						
Seroquel	357	170	110	109	292	130
Zomig	94	67	40	39	52	63
Others	9	6	50	33	2	100
<b>Total CNS</b>	<b>460</b>	<b>243</b>	<b>89</b>	<b>87</b>	<b>346</b>	<b>116</b>
<b>Pain, Infection and Other Pharma:</b>						
Diprivan	117	133	(12)	(13)	58	(13)
Merrem	69	65	6	8	8	(53)
Local anaesthetics	121	102	19	19	37	3
Other Pharma Products	68	104	(35)	(33)	18	(36)
<b>Total Pain, Infection and Other Pharma</b>	<b>375</b>	<b>404</b>	<b>(7)</b>	<b>(7)</b>	<b>121</b>	<b>(18)</b>
Salick Health Care	63	50	26	26	63	26

Astra Tech	43	36	19	2	3	-
Marlow Foods	29	26	12	4	1	-
<b>Total</b>	<b>4,901</b>	<b>4,366</b>	<b>12</b>	<b>10</b>	<b>2,564</b>	<b>16</b>

n/m not meaningful

### Convenience Translation of Key Financial Information

For the three months ended 31 December	2002 \$m	2001 (restated) \$m	2002 £m	2001 (restated) £m	2002 SEKm	2001 (restated) SEKm
<b>Total Sales</b>	4,901	4,366	3,045	2,713	42,982	38,290
<b>Operating profit before exceptional items (EI)</b>	1,074	1,090	667	677	9,419	9,559
<b>Profit before tax on continuing operations before EI</b>	1,081	1,102	672	685	9,480	9,665
<b>Net profit for the period</b>	428	726	266	451	3,754	6,367
<b>Earnings per Ordinary Share pre EI</b>	\$0.45	\$0.45	£0.28	£0.28	SEK3.95	SEK3.95

For the year ended 31 December	2002 \$m	2001 (restated) \$m	2002 £m	2001 (restated) £m	2002 SEKm	2001 (restated) SEKm
<b>Total Sales</b>	17,841	16,222	11,086	10,080	156,466	142,267
<b>Operating profit before exceptional items (EI)</b>	4,356	4,156	2,707	2,582	38,202	36,448
<b>Profit before tax on continuing operations before EI</b>	4,387	4,269	2,726	2,653	38,474	37,439
<b>Net profit for the year</b>	2,836	2,906	1,762	1,806	24,872	25,486
<b>Basic earnings per Ordinary Share</b>	\$1.64	\$1.65	£1.02	£1.03	SEK14.38	SEK14.47
<b>Earnings per Ordinary Share pre EI</b>	\$1.84	\$1.73	£1.14	£1.08	SEK16.14	SEK15.17
<b>Dividend per Ordinary Share</b>	\$0.70	\$0.70	43.2p	49.3p	SEK6.20	SEK7.45
<b>Net cash inflow from operating activities</b>	5,593	3,762	3,475	2,338	49,051	32,993
<b>Decrease in cash</b>	(22)	(396)	(14)	(246)	(193)	(3,473)
<b>Shareholders' funds – equity interests 31 December</b>	11,172	9,586	6,942	5,957	97,978	84,069

Sterling (£) and Swedish Kronor equivalents are shown for convenience and have been calculated using the current period end rates of \$1=£0.621388 and \$1=SEK8.77, respectively. Dividend per Ordinary Share is shown as the actual amount payable using the rates at the date of declaration of the dividend.

## Information for US Investors

### RECONCILIATION TO UNITED STATES ACCOUNTING PRINCIPLES

The Group profit and loss account and Group balance sheet set out on pages 9, 10 and 11 are prepared in accordance with generally accepted accounting principles in the United Kingdom (UK GAAP) which differ in certain material respects from those generally accepted in the United States (US GAAP). The differences as they apply to AstraZeneca PLC are explained in the Group's 2001 Annual Report and Form 20-F except that, in the current year, AstraZeneca adopted SFAS No141 'Business Combinations' and SFAS No142 'Goodwill and Other Intangible Assets'. As a result goodwill is no longer amortised but tested annually for impairment. The effect has been to increase profit by approximately \$755m. The approximate effects on Group income and shareholders' equity of the GAAP differences are shown below.

Income attributable to Shareholders	2002 \$m	2001 \$m
Net income for the year under UK GAAP (2001 restated)	2,836	2,906
Adjustments to conform to US GAAP		
Purchase accounting adjustments, (including goodwill and intangibles);		
- deemed acquisition of Astra		
- amortisation and other acquisition adjustments	(864)	(1,514)
- others	55	-
Capitalisation, less disposals and amortisation of interest	46	57
Deferred taxation		
- on fair value of Astra	239	249
- others	(99)	(198)
Pension expense	(50)	(33)
Post-retirement benefits/plan amendment	4	4
Software costs capitalised	(46)	(10)
Restructuring costs	-	(22)
Share based compensation	33	(7)
Fair value of derivative financial instruments	93	18
Deferred income recognition	61	(75)
Unrealised losses on foreign exchange and others	(1)	(10)
<b>Net income before cumulative effect of change in accounting policy</b>	<b>2,307</b>	<b>1,365</b>
Cumulative effect of change in accounting policy, net of tax, on adoption of SFAS No. 133	-	32
Net income in accordance with US GAAP	2,307	1,397
Net income per Ordinary Share under US GAAP (basic)	\$1.33	\$0.79
Net income per Ordinary Share under US GAAP (diluted)	\$1.33	\$0.79

## RECONCILIATION TO UNITED STATES ACCOUNTING PRINCIPLES

Shareholders' equity	31 Dec 2002 \$m	31 Dec 2001 \$m
Shareholders' equity under UK GAAP (2001 restated)	11,172	9,586
Adjustment to conform to US GAAP		
Purchase accounting adjustments, (including goodwill and intangibles);		
- deemed acquisition of Astra		
- goodwill	12,692	11,062
- tangible and intangible fixed assets	7,707	8,139
- others	86	31
Capitalisation, less disposals and amortisation of interest	238	192
Deferred taxation		
- on fair value of Astra	(2,305)	(2,313)
- others	(159)	(68)
Dividend	808	820
Pension expense	(271)	(162)
Post-retirement benefits/plan amendment	(24)	(28)
Software costs capitalised	64	110
Fair value of derivative financial instruments	99	50
Deferred income recognition	(14)	(75)
Others	90	58
<b>Shareholders' equity in accordance with US GAAP</b>	<b>30,183</b>	<b>27,402</b>

## Shareholder Information

### ANNOUNCEMENTS AND MEETINGS

---

Announcement of first quarter 2003 results	30 April 2003
Annual General Meeting 2003	30 April 2003
Announcement of second quarter and half year 2003 results	24 July 2003
Annual Business Review 2003	2 October 2003
Announcement of third quarter and nine months 2003 results	23 October 2003

### DIVIDENDS

---

The record date for the first interim dividend paid on 7 October 2002 (in the UK, Sweden and the US) was 23 August 2002. Ordinary Shares traded ex-dividend on the London and Stockholm Stock Exchange from 21 August 2002. ADRs traded ex-dividend on the New York Stock Exchange from the same date.

The record date for the second interim dividend for 2002 payable on 7 April 2003 (in the UK, Sweden and the US) will be 21 February 2003. Ordinary Shares will trade ex-dividend on the London and Stockholm Stock Exchange from 19 February 2003. ADRs will trade ex-dividend on the New York Stock Exchange from the same date.

Future dividends will normally be paid as follows:

First interim	Announced in July and paid in October
Second interim	Announced in January and paid in April.

### TRADE MARKS

---

The following brand names used in this interim report are trade marks of the AstraZeneca group of companies:

**Accolate Arimidex Astra Tech Atacand Atacand HCT Casodex Crestor Diprivan Exanta Faslodex Iressa Losec Merrem Nexium Nolvadex Oxis Plendil Prilosec Pulmicort Pulmicort Respules Pulmicort Turbuhaler Rhinocort Rhinocort Aqua Seloken Seroquel Symbicort Tenormin Toprol-XL Zestril Zoladex Zomig Zomig ZMT Zomig Rapimelt**

### ADDRESSES FOR CORRESPONDENCE

---

<b>Registrar and Transfer Office</b>	<b>Depository for ADRs</b>	<b>Registered Office</b>	<b>Swedish Securities Register Centre</b>
The AstraZeneca Registrar Lloyds TSB Registrars The Causeway Worthing West Sussex BN99 6DA Tel: +44 (0)121 433 8000	JPMorgan Chase Bank PO Box 43013 Providence, RI 02940-3013 US Tel: +1 (781) 575 4328	15 Stanhope Gate London W1K 1LN UK Tel: +44 (0)20 7304 5000	VPC AB PO Box 7822 S-103 97 Stockholm Sweden Tel: +46 (0)8 402 9000

### CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

---

In order to utilise the 'Safe Harbor' provisions of the United States Private Securities Litigation Reform Act of 1995, AstraZeneca is providing the following cautionary statement. This Preliminary Report contains forward-looking statements with respect to the financial condition, results of operations and businesses of AstraZeneca. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims and exposure to environmental liability.